Key result
Left ventricular assist device support significantly decreased the number of NF-kappaB positive cardiomyocyte nuclei in 15 of 16 patients with end-stage heart failure.
Why the study?
Does LVAD support reduce NF-kappaB activation in patients with end-stage heart failure?
Population
16 patients with end-stage heart failure
Comparison
Left ventricular assist device (LVAD) support vs Baseline (before LVAD support)
Design
Case_series
Authors
Loading...
LVAD support reduces NF-κB activation in failing hearts; hypothesis-generating for its role in reverse remodeling and as a therapeutic target.
Observational (n=16)
Does LVAD support reduce NF-kappaB activation in patients with end-stage heart failure?
LVAD support decreases NF-kappaB activation and cardiomyocyte diameter in failing human hearts, suggesting a molecular mechanism for reverse remodeling.
Florian Grabellus (2002) conducted an observational in End-stage heart failure (n=16). Left ventricular assist device (LVAD) support vs. Before LVAD support (baseline) was evaluated on Number of NF-kappaB positive cardiomyocyte nuclei. Left ventricular assist device support significantly decreased the number of NF-kappaB positive cardiomyocyte nuclei in 15 of 16 patients with end-stage heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: